Evidence map›Paper›PMID 32492981›Full record

ArticleCancers2020

Impact of CD56 Continuously Recognizable as Prognostic Value of Acute Promyelocytic Leukemia: Results of Multivariate Analyses in the Japan Adult Leukemia Study Group (JALSG)-APL204 Study and a Review of the Literature.

Akihiro Takeshita, Norio Asou, Yoshiko Atsuta, Hiroaki Furumaki, Toru Sakura, Yasunori Ueda, Masashi Sawa, Nobuaki Dobashi, Yasuhiro Taniguchi, Rikio Suzuki and 16 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 20 institutions in 1 country.

Akihiro TakeshitaTransfusion and Cell Therapy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Higashiku 431-3192, Japan.
Norio AsouInternational Medical Center, Saitama Medical University, 1397-1, Yamane, Hidaka 350-1298, Japan.
Yoshiko AtsutaThe Japanese Data Center for Hematopoietic Cell Transplantation, 1-1-20 Taikou-minami, Higashiku, Nagoya 461-0047, Japan.
Hiroaki FurumakiTransfusion and Cell Therapy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Higashiku 431-3192, Japan.
Toru SakuraHematology, Saiseikai Maebashi Hospital, 564-1, Kamishindenmachi, Maebashi 371-0821, Japan.
Yasunori UedaHematology/Oncology, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki 710-8602, Japan.
Masashi SawaHematology and Oncology, Anjo Kosei Hospital, 28 Higashikurokute, Anjochou, Anjo 446-8602, Japan.
Nobuaki DobashiClinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishisinbashi, Minatoku, Tokyo 105-8461, Japan.
Yasuhiro TaniguchiHematology and Rheumatology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Ohsakasayama 589-8511, Japan.
Rikio SuzukiHematology and Oncology, Tokai University School of Medicine, 143 Shimokasuya, Isahara 259-1193, Japan.
Masaru NakagawaHematology and Rheumatology, Nihon University School of Medicine, 30-1 Ohyaguchikamichou, Itabashiku, Tokyo 173-8610, Japan.
Shigehisa TamakiHematology, Japanese Red Cross Ise Hospital, 1-471-2 Funae, Ise 516-8512, Japan.
Maki HagiharaHematology and Clinical Immunology, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawaku, Yokohama 236-0004, Japan.
Katsumichi FujimakiHematology, Fujisawa City Hospital, 2-6-1 Fujisawa, Fujisawa 251-8550, Japan.
Hitoshi MinamiguchiHematology, Shiga University of Medical Science, Seta-Tsukinowa, Otsu 520-2192, Japan.
Hiroyuki FujitaHematology, Saiseikai Yokohama Nanbu Hospital, 3-2-10 Kounandai, Kounanku, Yokohama 234-0054, Japan.
Masamitsu YanadaHematology and Cell Therapy, Aichi Cancer Center, 1-1 Kanokoden, Chikusaku, Nagoya 464-8681, Japan.
Yoshinobu MaedaHematology, Oncology and Respiratory Medicine, Okayama University Medical School, 2-5-1 Shikatachou, Kitaku, Okayama 700-8558, Japan.
Noriko UsuiClinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishisinbashi, Minatoku, Tokyo 105-8461, Japan.
Yukio KobayashiNational Cancer Center Hospital, 5-1-1 Tsukiji, Chuouku, Tokyo 104-0045, Japan.
Hitoshi KiyoiHematology and Oncology, Nagoya University Graduate School of Medicine, 65 Tsurumaichou, Showaku, Nagoya 466-8550, Japan.
Shigeki OhtakeKanazawa University, Kakumamachi, Kanazawa 920-1192, Japan.
Itaru MatsumuraHematology and Rheumatology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Ohsakasayama 589-8511, Japan.
Tomoki NaoeNational Hospital Organization Nagoya Medical Center, 4-1-1 Sannomaru, Nakaku, Nagoya 460-0001, Japan.
Yasushi MiyazakiHematology, Atomic Bomb Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.
The Japan Adult Leukemia Study GroupJALSG office, 3-6-35 Nishiki, Nakaku, Nagoya 460-0003, Japan.
Hamamatsu University School of Medicine · JPJikei University School of Medicine · JPKindai University · JPAichi Cancer Center · JPAnjo Kosei Hospital · JPFujisawa City Hospital · JPGunma Saiseikai Maebashi Hospital · JPIse Red Cross Hospital · JPKanazawa University · JPKurashiki Central Hospital · JPNagasaki University · JPNagoya University · JPNagoya University of Foreign Studies · JPNational Hospital Organization · JPNihon University · JPOkayama University · JPSaiseikai Ibaraki Hospital · JPSaitama Medical University · JPShiga University of Medical Science · JPThe Japanese Data Center for Hematopoietic Cell Transplantation · JP

Funding

the Japan Agency for Medical Research and Development (AMED) 17ck0106251the Japanese Ministry of Health, Labor and Welfare Clinical Cancer Research 23-004the National Cancer Center Research and Development Fund 23-A-23the National Cancer Center Research and Development Fund 26-A-24
6 · The paper itself

Abstract

backgroundAfter long-term analysis of the JALSG-APL204 study we recently reported that maintenance therapy with tamibarotene was more effective than all-trans retinoic acid (ATRA) by reducing relapse in APL patients. Here, the clinical significance of other important prognostic factors was evaluated with multivariate analyses. PATIENTS AND

methodsNewly diagnosed acute promyelocytic leukemia (APL) patients were registered with the study. Induction was composed of ATRA and chemotherapy. Patients who achieved molecular remission after consolidation were randomly assigned to maintenance with tamibarotene or ATRA.

resultsOf the 344 eligible patients, 319 (93%) achieved complete remission (CR). After completing consolidation, 269 patients underwent maintenance random assignment-135 to ATRA, and 134 to tamibarotene. By multivariate analysis, overexpression of CD56 in blast was an independent unfavorable prognostic factor for relapse-free survival (RFS) (

Indexed as

acute promyelocytic leukemiaCD56multivariate analysisprognosistamibarotene

Identifiers

PMID32492981
PMCPMC7352829
OpenAlexW3029238350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.